Elsevier

Cancer Treatment Reviews

Volume 35, Issue 5, August 2009, Pages 463-474
Cancer Treatment Reviews

LABORATORY CLINICAL INTERFACE
Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer

https://doi.org/10.1016/j.ctrv.2009.03.004Get rights and content

Summary

The enumeration of circulating tumor cells has long been regarded as an attractive diagnostic tool, as circulating tumor cells are thought to reflect aggressiveness of the tumor and may assist in therapeutic decisions in patients with solid malignancies.

However, implementation of this assay into clinical routine has been cumbersome, as a validated test was not available until recently. Circulating tumor cells are rare events which can be detected specifically only by using a combination of surface and intracellular markers, and only recently a number of technical advances have made their reliable detection possible. Most of these new techniques rely on a combination of an enrichment and a detection step.

This review addresses the assays that have been described so far in the literature, including the enrichment and detection steps and the markers used in these assays. We have focused on breast cancer as most clinical studies on CTC detection so far have been done in these patients.

Introduction

The outcome of breast cancer largely depends on the development of metastases in the course of the disease. Given this vital importance of metastases, means to detect and monitor their existence are continuously sought for. The detection of circulating tumor cells (CTCs) is one field of research focusing on a new method to detect metastatic disease earlier, less invasive and more reliably than currently available conventional methods, such as clinical presentation, radiographic evaluation and serum tumor markers do. CTCs are defined as tumor cells circulating in the peripheral blood of patients, shed from either the primary tumor or its metastases. Numerous efforts have been made to reliably detect and quantify CTCs in peripheral blood, but development of a suitable assay has proven to be difficult. Unfortunately, there is not one specific feature that universally distinguishes CTCs from blood cells. Ideally, a specific marker would be identified, which is expressed in every cell of every breast cancer type. In reality, different histological and molecular types of tumors express different arrays of markers, and marked heterogeneity of expression exists even within one histological distinct tumor type. Another challenge regarding sensitivity of assays is the fact that CTCs are rare events, with numbers as low as one CTC in 106–107 leukocytes.1 In spite of these challenging characteristics, the importance of detecting and enumerating CTCs in breast cancer has been established in several clinical studies, showing a correlation with decreased progression-free survival (PFS) and overall survival (OS).[2], [3] In addition to detection and enumeration, molecular characterization of CTCs provides a second much-anticipated application in oncology. Currently, we are dependent on the primary tumor for molecular characteristics in order to determine the type of therapy the patient will benefit from most. However, tumor genotype and/or phenotype may change in the course of treatment as indicated by therapy resistance. CTCs might function as a real-time biopsy of tumor load, and enable oncologists to make better-informed choices regarding therapy.

In addition to CTCs, disseminated tumor cells (DTCs), i.e., isolated tumor cells in bone marrow, are thought to reflect the metastatic potential of tumors. DTCs have also been correlated with prognosis[4], [5], but for their detection an invasive diagnostic procedure, bone marrow aspiration, is necessary. This requirement makes their implementation in the clinic more troublesome. By contrast, CTCs have the advantage of being readily available in peripheral blood and given this, together with mounting evidence supporting their clinical feasibility as reviewed here, the detection of CTCs is anticipated to gain clinical relevance shortly. For a comprehensive review on DTCs and their complementary role to CTCs, we refer to the recent review by Riethdorf et al.6

Here we will discuss the principals and technical aspects of the different techniques available for detecting CTCs, in addition to the most frequently used markers in these techniques. Furthermore, we will discuss clinical studies showing the utility of CTC detection in breast cancer patients with these techniques. Reviews focusing on the detection techniques of both DTCs and CTCs, as well as biological relevance, have been published recently.[7], [8]

Section snippets

Detection of circulating tumor cells

In general, methods for CTC detection can be divided into cytometric (i.e., whole-cell based) and nucleic-acid based techniques. Both techniques usually include an enrichment step and a detection step.

As CTCs are rare events occurring at rates as low as one cell per 106–107 leukocytes, enrichment is generally needed to increase sensitivity to an acceptable level. One type of enrichment relies upon the selection of target cells with tumor-specific markers (immunoseparation). Other methods for

Increasing assay sensitivity: enrichment techniques

As mentioned before, enrichment can be based on morphologic cell characteristics, such as size or density, or on immunoseparation, using magnetic beads, ferrofluids or rosettes (see Fig. 1, Fig. 2).

Cytometric methods

The presence of tumor cells in the bone marrow was first identified using conventional imaging techniques.19 Building on this, detecting tumor cells in the circulation was attempted using simple hematoxylin and eosin staining.20 This exhaustive method consisted of visually identifying large numbers of gradient-separated cells and comparing them with primary tumor cells morphologically. Nowadays, as previously mentioned, detection of CTCs occurs on a cytometric or a nucleic-acid basis.

Cytometric

Combined enrichment and detection techniques

CellSearch (Veridex™, Warren, PA) is a semi-automated technology by which whole blood is enriched for CTCs by adding ferrofluids loaded with antibodies directed towards EpCAM. Currently, CellSearch is the only FDA-approved assay for CTC detection. CTCs in the enriched population are stained with CK and DAPI using fluorescent antibodies, while hematopoietic cells are counterstained with CD45. The CK+/DAPI+/CD45- cells are then enumerated with an automated fluorescence microscope. The

Markers

The effectiveness of tumor cell enrichment and detection depends upon the choice of markers, tools to identify and characterize CTCs. Many different markers have been explored in the field of CTCs. To date, no one marker has proven to be ideal for the detection of breast cancer CTCs. This is not unexpected given the heterogeneity of the disease and the rarity of CTCs. In breast cancer, a wide array of markers has been studied, especially with nucleic-acid based techniques. In Table 3, we

Clinical applications of CTC detection

The presence of occult metastases cannot be deduced from the finding of CTCs alone, as CTCs must pass through several stages before forming a metastatic colony. Cells must extravasate from the circulation into target organs and subsequently proliferate whilst evading immunological response and overcoming metabolic difficulties. It has been estimated that only one in 10,000 CTCs is able to form a metastasis.50

Despite all this, the clinical usefulness of CTC detection has been demonstrated in

Neoadjuvant setting

For patients presenting with locally advanced breast cancer, i.e., tumors presenting with extensive regional lymph node involvement, skin involvement or a large size (>5 cm), resection of the primary tumor is frequently either not possible or only at the cost of an amputation of the breast. Systemic therapy given prior to management of the primary tumor, also known as neoadjuvant therapy, aims to reduce tumor size thereby rendering the residual tumor amendable for a breast-conserving resection.

Adjuvant setting

Adjuvant chemotherapy refers to systemic therapy after primary surgery for early stage breast cancer patients who are considered to have a high risk for metastatic disease developing from micro-metastases that are already present at initial presentation. The intent of adjuvant therapy is to cure patients by eradicating these micrometastases. Currently, it is not possible to adequately identify patients who do not harbor micrometastases and therefore should be spared from adjuvant therapy and

CTC detection in metastatic breast cancer

In metastatic disease, the intention of treatment is essentially palliative, striving to optimize quality rather than duration of life. Assessing prognosis in patients with metastatic breast cancer with CTCs can be helpful in the individualized management of these patients. In a multicenter, prospective study conducted by Cristofanilli et al.,78 CTC count was assessed using CellSearch in 177 progressive metastatic breast cancer patients who were to start a new line of systemic therapy. CTCs

Discussion

Circulating tumor cells are being recognized as a promising diagnostic tool in oncology, and thus many efforts have been made to detect them reliably. In breast cancer, several techniques (both cytometric and nucleic-acid based) have been explored in different settings yielding interesting results. However, in addition to independent confirmation of these results, several issues remain to be resolved.

Studies have shown remarkably varying CTC counts, ranging from <5 to thousands per ml in the

Conflicts of interest statement

None declared.

Acknowledgement

This study was supported in part by The Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO).

References (169)

  • C.A. Klein et al.

    Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer

    Lancet

    (2002)
  • Y. Wang et al.

    Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

    Lancet

    (2005)
  • A. Schoenfeld et al.

    The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19

    Eur J Cancer

    (1997)
  • H. Taubert et al.

    Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases

    Gynecol Oncol

    (2004)
  • M. Cristofanilli et al.

    Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

    J Clin Oncol

    (2005)
  • J.B. Smerage et al.

    The prognostic implications of circulating tumor cells in patients with breast cancer

    Cancer Invest

    (2008)
  • S. Braun et al.

    Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

    N Engl J Med

    (2000)
  • G. Gebauer et al.

    Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up

    J Clin Oncol

    (2001)
  • S. Riethdorf et al.

    Review: biological relevance of disseminated tumor cells in cancer patients

    Int J Cancer

    (2008)
  • K. Pantel et al.

    Detection, clinical relevance and specific biological properties of disseminating tumour cells

    Nat Rev Cancer

    (2008)
  • C. Alix-Panabieres et al.

    Circulating tumor cells and bone marrow micrometastasis

    Clin Cancer Res

    (2008)
  • T.G. Ntouroupi et al.

    Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope

    Br J Cancer

    (2008)
  • B. Naume et al.

    Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood

    J Hematother

    (1997)
  • A.E. Ring et al.

    Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques

    Br J Cancer

    (2005)
  • B.M. Smith et al.

    Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques

    J Clin Oncol

    (2000)
  • A.C. Lambrechts et al.

    Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells

    Breast Cancer Res Treat

    (1999)
  • K. Jacob et al.

    Circulating tumor cells: detection, molecular profiling and future prospects

    Expert Rev Proteomics

    (2007)
  • W.J. Allard et al.

    Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

    Clin Cancer Res

    (2004)
  • M. Tewes et al.

    Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

    Breast Cancer Res Treat

    (2008)
  • K. Rohr et al.

    Tumorzellen im Sternalpunktat

    Dtsch Arch Klin Med

    (1936)
  • The circulating cancer cell. Lancet...
  • E. Borgen et al.

    Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase

    J Pathol

    (1998)
  • E. Borgen et al.

    A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow

    Cytometry B Clin Cytom

    (2006)
  • W. Brugger et al.

    Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells

    J Clin Oncol

    (1999)
  • Sieuwerts A, Kraan Jaco, Bolt Joan, van der Spoel Petra, Elstrodt Fons, Schutte Mieke, et al. Anti-epithelial cell...
  • R.T. Krivacic et al.

    A rare-cell detector for cancer

    Proc Natl Acad Sci USA

    (2004)
  • K. Pachmann et al.

    Standardized quantification of circulating peripheral tumor cells from lung and breast cancer

    Clin Chem Lab Med

    (2005)
  • K. Pachmann et al.

    An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells [CETC) for monitoring of adjuvant therapy in breast cancer

    J Cancer Res Clin Oncol

    (2008)
  • G. Deng et al.

    Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients

    Breast Cancer Res

    (2008)
  • S.K. Kraeft et al.

    Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system

    Clin Cancer Res

    (2000)
  • W.E. Mesker et al.

    Detection of immunocytochemically stained rare events using image analysis

    Cytometry

    (1994)
  • S.A. Leon et al.

    Free DNA in the serum of cancer patients and the effect of therapy

    Cancer Res

    (1977)
  • R.W. Chiu et al.

    Quantitative analysis of circulating mitochondrial DNA in plasma

    Clin Chem

    (2003)
  • V. Combaret et al.

    Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients

    Cancer Res

    (2002)
  • T. Gotoh et al.

    Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction

    J Clin Oncol

    (2005)
  • M.J. Slade et al.

    Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer

    J Clin Oncol

    (1999)
  • R. Jung et al.

    Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro

    Br J Cancer

    (1998)
  • V.V. Iakovlev et al.

    Quantitative detection of circulating epithelial cells by Q-RT-PCR

    Breast Cancer Res Treat

    (2008)
  • G. Schleiermacher et al.

    Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor

    J Clin Oncol

    (2003)
  • S. Avigad et al.

    The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors

    Cancer

    (2004)
  • Cited by (0)

    c

    Erasmus MC, Daniel den Hoed Cancer Center, Room G4-83, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Tel.: +31 10 7041331; fax: +31 10 7041003.

    d

    Erasmus MC, Josephine Nefkens Institute and Cancer Genomics Centre, Room BE-426, Dr. Molenwaterplein 50, 3015 GE Rotterdam, The Netherlands. Tel.: +31 10 7044369; fax: +31 10 7034627.

    e

    Erasmus MC, Daniel den Hoed Cancer Center, Room D2-80a, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Tel.: +31 10 7041418; fax: +31 10 7041005.

    View full text